首页 > 最新文献

Journal of Contemporary Brachytherapy最新文献

英文 中文
Investigation of in vivo source tracking error thresholds for interstitial and intra-cavitary high-dose-rate cervical brachytherapy. 间质和腔内高剂量率宫颈近距离放射治疗的体内放射源跟踪误差阈值研究。
IF 1.1 4区 医学 Q4 ONCOLOGY Pub Date : 2022-12-01 Epub Date: 2022-12-30 DOI: 10.5114/jcb.2022.123977
Yashiv Dookie, Joel Poder, Simon Downes, Dean Cutajar, Anatoly Rosenfeld

Purpose: The purpose of this study was to determine a comprehensive in vivo source tracking error thresholds in high-dose-rate (HDR) brachytherapy for cervical cancer. Achieving this enables the definition of an action level for imminent in vivo source tracking technologies and treatment monitoring devices, preventing clinically relevant changes to the applied dose.

Material and methods: Retrospective HDR interstitial (n = 10) and intra-cavitary (n = 20) cervical brachytherapy patients were randomly selected to determine the feasibility of implementing in vivo source tracking error thresholds. A script was developed to displace all dwell positions in each treatment plan, along all major axes from their original position. Dose-volume histogram (DVH) indices were calculated without re-optimization of modified plans to determine the appropriate in vivo source tracking error thresholds in each direction.

Results: In vivo source tracking error thresholds were directionally dependent; the smallest were found to be 2 mm in the anterior and posterior directions for both interstitial and intra-cavitary treatments. High-risk clinical treatment volume (HR-CTV) coverage was significantly impacted by displacements of 4 to 5 mm along each axis. Critically, there was a large variation in DVH metrics with displacement due to change in dwell weightings and patient anatomy.

Conclusions: Determining the dosimetric impact of dwell position displacement provides a clinical benchmark for the development of pre-treatment verification devices and an action level for real-time treatment monitoring. It was established that an in vivo source tracking error threshold needs to be patient-specific. In vivo source tracking error thresholds should be determined for each patient, and can be conducted with extension of the method established in this work.

目的:本研究旨在确定宫颈癌高剂量率(HDR)近距离放射治疗中的综合体内放射源跟踪误差阈值。这样就能为即将采用的体内放射源跟踪技术和治疗监测设备确定一个行动水平,防止应用剂量发生与临床相关的变化:材料和方法:随机选取回顾性 HDR 间质(n = 10)和腔内(n = 20)宫颈近距离治疗患者,以确定实施体内放射源跟踪误差阈值的可行性。我们开发了一个脚本,将每个治疗方案中的所有停留位置沿所有主要轴线从原始位置移位。在不对修改后的计划进行重新优化的情况下,计算剂量-体积直方图(DVH)指数,以确定每个方向上合适的体内放射源追踪误差阈值:体内放射源跟踪误差阈值与方向有关;发现间隙治疗和腔内治疗前后方向的误差阈值最小为 2 毫米。高风险临床治疗容积(HR-CTV)的覆盖范围受到沿每个轴方向 4 至 5 毫米位移的显著影响。重要的是,由于驻留权重和患者解剖结构的变化,DVH指标随位移的变化很大:结论:确定驻留位置位移对剂量测定的影响为开发治疗前验证设备提供了临床基准,也为实时治疗监测提供了行动级别。研究表明,体内源追踪误差阈值必须针对患者的具体情况。体内源追踪误差阈值应根据每位患者的情况来确定,并可通过扩展本研究中建立的方法来实现。
{"title":"Investigation of in vivo source tracking error thresholds for interstitial and intra-cavitary high-dose-rate cervical brachytherapy.","authors":"Yashiv Dookie, Joel Poder, Simon Downes, Dean Cutajar, Anatoly Rosenfeld","doi":"10.5114/jcb.2022.123977","DOIUrl":"10.5114/jcb.2022.123977","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to determine a comprehensive <i>in vivo</i> source tracking error thresholds in high-dose-rate (HDR) brachytherapy for cervical cancer. Achieving this enables the definition of an action level for imminent <i>in vivo</i> source tracking technologies and treatment monitoring devices, preventing clinically relevant changes to the applied dose.</p><p><strong>Material and methods: </strong>Retrospective HDR interstitial (<i>n</i> = 10) and intra-cavitary (<i>n</i> = 20) cervical brachytherapy patients were randomly selected to determine the feasibility of implementing <i>in vivo</i> source tracking error thresholds. A script was developed to displace all dwell positions in each treatment plan, along all major axes from their original position. Dose-volume histogram (DVH) indices were calculated without re-optimization of modified plans to determine the appropriate <i>in vivo</i> source tracking error thresholds in each direction.</p><p><strong>Results: </strong><i>In vivo</i> source tracking error thresholds were directionally dependent; the smallest were found to be 2 mm in the anterior and posterior directions for both interstitial and intra-cavitary treatments. High-risk clinical treatment volume (HR-CTV) coverage was significantly impacted by displacements of 4 to 5 mm along each axis. Critically, there was a large variation in DVH metrics with displacement due to change in dwell weightings and patient anatomy.</p><p><strong>Conclusions: </strong>Determining the dosimetric impact of dwell position displacement provides a clinical benchmark for the development of pre-treatment verification devices and an action level for real-time treatment monitoring. It was established that an <i>in vivo</i> source tracking error threshold needs to be patient-specific. <i>In vivo</i> source tracking error thresholds should be determined for each patient, and can be conducted with extension of the method established in this work.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/4a/JCB-14-49847.PMC9924149.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9316974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual-source strength seed loading for eye plaque brachytherapy using eye physics eye plaques: A feasibility study. 双源强度种子负荷用于眼物理眼斑近距离治疗的可行性研究。
IF 1.4 4区 医学 Q3 Medicine Pub Date : 2022-12-01 DOI: 10.5114/jcb.2022.123979
Sheridan G Meltsner, David G Kirsch, Miguel A Materin, Yongbok Kim, Yang Sheng, Oana Craciunescu

Purpose: This study quantifies the dosimetric impact of incorporating two iodine-125 (125I) seed source strengths in Eye Physics eye plaques for treatment of uveal melanoma.

Material and methods: Plaque Simulator was used to retrospectively plan 15 clinical cases of three types: (1) Shallow tumors (< 5.5 mm) with large base dimensions (range, 16-19 mm); (2) Tumors near the optic nerve planned with notched plaques; and (3) Very shallow (< 3.0 mm) tumors with moderate base dimensions (range, 13.5-15.5 mm) planned with larger plaques than requested by the ocular oncologist. Circular plaques were planned with outer ring sources twice the source strength of inner sources, and notched plaques with the six seeds closest to the notch at twice the source strength.

Results: In cases of type (1), the dual-source strength plan decreased prescription depth, and doses to critical structures were lower: inner sclera -25% ±2%, optic disc -7% ±3%, and fovea -6% ±3%. In four out of five cases of type (2), the dual-source strength plan decreased prescription depth, and dose to inner sclera was lower (-22% ±5%), while dose to optic disc (17% ±7%) and fovea (20% ±12%) increased. In cases of type (3), a smaller dual-source strength plaque was used, and scleral dose was lower (-45% ±3%), whereas dose to optic disc (1% ±14%) and fovea (5% ±5%) increased.

Conclusions: Dual-source strength loading as described in this study can be used to cover tumor margins and decrease dose to sclera, and therefore the adjacent retina, but can either decrease or increase radiation dose to optic disc and fovea depending on location and size of the tumor. This technique may allow the use of a smaller plaque, if requested by the ocular oncologist. Clinical determination to use this technique should be performed on an individual basis, and additional QA steps are required. Integrating the use of volumetric imaging may be warranted.

目的:本研究量化了两种碘-125 (125I)种子源强度在眼物理眼斑中治疗葡萄膜黑色素瘤的剂量学影响。材料与方法:采用斑块模拟器对15例临床病例进行回顾性规划,分为三类:(1)基底尺寸较大(范围16 ~ 19 mm)的浅部肿瘤(< 5.5 mm);(2)视神经附近肿瘤伴切口斑块;(3)非常浅(< 3.0 mm)的肿瘤,其基础尺寸适中(范围13.5-15.5 mm),计划的斑块比眼科肿瘤学家要求的要大。用两倍于内源强度的外环源来规划圆形斑块,用两倍于内源强度的最靠近缺口的6颗种子来规划缺口斑块。结果:在(1)型病例中,双源强度计划降低了处方深度,对关键结构的剂量较低:巩膜内-25%±2%,视盘-7%±3%,中央窝-6%±3%。(2)型5例中有4例双源强度方案降低处方深度,巩膜内剂量较低(-22%±5%),视盘剂量增加(17%±7%),中央窝剂量增加(20%±12%)。在(3)型病例中,使用较小的双源强度斑块,巩膜剂量较低(-45%±3%),而视盘剂量(1%±14%)和中央凹剂量(5%±5%)增加。结论:本研究中描述的双源强度负荷可用于覆盖肿瘤边缘,减少巩膜和邻近视网膜的辐射剂量,但可根据肿瘤的位置和大小减少或增加视盘和中央窝的辐射剂量。如果眼科肿瘤学家要求,这种技术可以使用更小的斑块。使用该技术的临床决定应在个体基础上进行,并需要额外的QA步骤。整合使用体积成像可能是必要的。
{"title":"Dual-source strength seed loading for eye plaque brachytherapy using eye physics eye plaques: A feasibility study.","authors":"Sheridan G Meltsner,&nbsp;David G Kirsch,&nbsp;Miguel A Materin,&nbsp;Yongbok Kim,&nbsp;Yang Sheng,&nbsp;Oana Craciunescu","doi":"10.5114/jcb.2022.123979","DOIUrl":"https://doi.org/10.5114/jcb.2022.123979","url":null,"abstract":"<p><strong>Purpose: </strong>This study quantifies the dosimetric impact of incorporating two iodine-125 (<sup>125</sup>I) seed source strengths in Eye Physics eye plaques for treatment of uveal melanoma.</p><p><strong>Material and methods: </strong>Plaque Simulator was used to retrospectively plan 15 clinical cases of three types: (1) Shallow tumors (< 5.5 mm) with large base dimensions (range, 16-19 mm); (2) Tumors near the optic nerve planned with notched plaques; and (3) Very shallow (< 3.0 mm) tumors with moderate base dimensions (range, 13.5-15.5 mm) planned with larger plaques than requested by the ocular oncologist. Circular plaques were planned with outer ring sources twice the source strength of inner sources, and notched plaques with the six seeds closest to the notch at twice the source strength.</p><p><strong>Results: </strong>In cases of type (1), the dual-source strength plan decreased prescription depth, and doses to critical structures were lower: inner sclera -25% ±2%, optic disc -7% ±3%, and fovea -6% ±3%. In four out of five cases of type (2), the dual-source strength plan decreased prescription depth, and dose to inner sclera was lower (-22% ±5%), while dose to optic disc (17% ±7%) and fovea (20% ±12%) increased. In cases of type (3), a smaller dual-source strength plaque was used, and scleral dose was lower (-45% ±3%), whereas dose to optic disc (1% ±14%) and fovea (5% ±5%) increased.</p><p><strong>Conclusions: </strong>Dual-source strength loading as described in this study can be used to cover tumor margins and decrease dose to sclera, and therefore the adjacent retina, but can either decrease or increase radiation dose to optic disc and fovea depending on location and size of the tumor. This technique may allow the use of a smaller plaque, if requested by the ocular oncologist. Clinical determination to use this technique should be performed on an individual basis, and additional QA steps are required. Integrating the use of volumetric imaging may be warranted.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/0a/JCB-14-49849.PMC9924146.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9316973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Radiation exposure to the kidney with interstitial iridium-192 high-dose-rate brachytherapy: Extent and rare morphologic changes of radiation nephropathy. 采用间质性铱-192高剂量率近距离放射治疗照射肾脏:放射性肾病的范围和罕见的形态学改变。
IF 1.4 4区 医学 Q3 Medicine Pub Date : 2022-12-01 DOI: 10.5114/jcb.2022.123970
Christine March, Maximilian Thormann, Peter Hass, Max Seidensticker, Christian Gross, Jazan Omari, Maciej Pech, Robert Damm

Purpose: We sought to investigate functional parameters and morphologic changes of the renal parenchyma after treatment with image-guided brachytherapy using single-fraction irradiation (high-dose-rate brachytherapy - HDR-BT) of primary kidney lesions, and primary and secondary lesions of the liver, lymph node, and adrenal gland close to renal structures.

Material and methods: Patients ineligible for surgery were included. We prospectively investigated renal function loss within one year via renal scintigraphy and laboratory parameters (KDOQI stage). Radiation exposure to the kidney was measured by volume receiving 5 Gy (V5). We observed morphologic changes on CT or MRI, with follow-up every three months.

Results: In total, 35 patients were included (21 males, 14 females). Eight patients were treated for extra-renal malignancies. The mean V5 of the ipsilateral kidney was 70.0 ±42.4 ml equaling to 44.9% parenchymal volume. After renal treatment, V5 renal volume was 77.8 ±42.2 ml (48.7%) compared with 44.0 ±33.0 ml (32.0%) after extra-renal treatment. No significant reduction in KDOQI stage after 12 months of follow-up were found. Three patients developed morphologic changes in the renal parenchyma, with only one showing a decrease in renal function after 12 months.

Conclusions: CT-guided HDR-BT is a viable treatment modality for local ablative treatment of renal and adjacent masses, with no significant reduction of the KDOQI stage as a predictor for complications of chronic kidney disease. However, larger cohorts need to be analyzed to identify vulnerable patients, as in rare cases, plain dosimetry seems insufficient to predict renal function loss after HDR-BT.

目的:研究图像引导近距离放射治疗(高剂量率近距离放射治疗- HDR-BT)对原发性肾脏病变以及靠近肾脏结构的肝脏、淋巴结和肾上腺的原发性和继发性病变后肾实质的功能参数和形态学变化。材料和方法:纳入不符合手术条件的患者。我们通过肾显像和实验室参数(KDOQI分期)前瞻性地研究了一年内的肾功能丧失。肾脏的辐射暴露量以接受5gy (V5)的体积来测量。我们通过CT或MRI观察形态学改变,每3个月随访一次。结果:共纳入35例患者,其中男21例,女14例。8例患者接受肾外恶性肿瘤治疗。同侧肾脏V5平均值为70.0±42.4 ml,占实质体积的44.9%。肾脏治疗后V5肾容积为77.8±42.2 ml(48.7%),肾外治疗后V5肾容积为44.0±33.0 ml(32.0%)。随访12个月后,KDOQI分期未见明显降低。3例患者出现肾实质形态学改变,其中1例患者12个月后肾功能下降。结论:ct引导下的HDR-BT是一种可行的治疗方式,用于局部消融治疗肾脏和邻近肿块,并没有显著降低作为慢性肾脏疾病并发症预测因子的KDOQI分期。然而,需要对更大的队列进行分析以确定易感患者,因为在极少数情况下,普通剂量法似乎不足以预测HDR-BT后的肾功能丧失。
{"title":"Radiation exposure to the kidney with interstitial iridium-192 high-dose-rate brachytherapy: Extent and rare morphologic changes of radiation nephropathy.","authors":"Christine March,&nbsp;Maximilian Thormann,&nbsp;Peter Hass,&nbsp;Max Seidensticker,&nbsp;Christian Gross,&nbsp;Jazan Omari,&nbsp;Maciej Pech,&nbsp;Robert Damm","doi":"10.5114/jcb.2022.123970","DOIUrl":"https://doi.org/10.5114/jcb.2022.123970","url":null,"abstract":"<p><strong>Purpose: </strong>We sought to investigate functional parameters and morphologic changes of the renal parenchyma after treatment with image-guided brachytherapy using single-fraction irradiation (high-dose-rate brachytherapy - HDR-BT) of primary kidney lesions, and primary and secondary lesions of the liver, lymph node, and adrenal gland close to renal structures.</p><p><strong>Material and methods: </strong>Patients ineligible for surgery were included. We prospectively investigated renal function loss within one year <i>via</i> renal scintigraphy and laboratory parameters (KDOQI stage). Radiation exposure to the kidney was measured by volume receiving 5 Gy (V<sub>5</sub>). We observed morphologic changes on CT or MRI, with follow-up every three months.</p><p><strong>Results: </strong>In total, 35 patients were included (21 males, 14 females). Eight patients were treated for extra-renal malignancies. The mean V<sub>5</sub> of the ipsilateral kidney was 70.0 ±42.4 ml equaling to 44.9% parenchymal volume. After renal treatment, V<sub>5</sub> renal volume was 77.8 ±42.2 ml (48.7%) compared with 44.0 ±33.0 ml (32.0%) after extra-renal treatment. No significant reduction in KDOQI stage after 12 months of follow-up were found. Three patients developed morphologic changes in the renal parenchyma, with only one showing a decrease in renal function after 12 months.</p><p><strong>Conclusions: </strong>CT-guided HDR-BT is a viable treatment modality for local ablative treatment of renal and adjacent masses, with no significant reduction of the KDOQI stage as a predictor for complications of chronic kidney disease. However, larger cohorts need to be analyzed to identify vulnerable patients, as in rare cases, plain dosimetry seems insufficient to predict renal function loss after HDR-BT.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b2/bf/JCB-14-49840.PMC9924155.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10769337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Computed tomography-guided iodine-125 radioactive seed implantation in small-cell lung cancer: A retrospective study. ct引导下碘125放射性粒子植入治疗小细胞肺癌的回顾性研究。
IF 1.4 4区 医学 Q3 Medicine Pub Date : 2022-12-01 DOI: 10.5114/jcb.2022.123973
Mengjie Li, Peng Liu, Huan Wang, Biao Wang, Jie Zhou, Yuzhen Jin, Cuicui Wang, Jian Yang, Ping Zhang

Purpose: To explore the efficacy of computed tomography (CT)-guided iodine-125 (125I) radioactive seed implantation for the treatment of small-cell lung cancer (SCLC).

Material and methods: A total of 12 SCLC patients were retrospectively enrolled. All patients underwent CT-guided 125I seed implantation therapy, and were followed up until death, the last visit time, or study end time. Primary endpoint was the overall response rate (ORR). Secondary endpoints were local control rate (LCR), progression-free survival (PFS), overall survival (OS), and safety.

Results: All patients were successfully implanted with 125I radioactive seeds. The ORR at 2, 6, 12, and 24 months after implantation was 83.3%, 63.6%, 50%, and 40%, respectively; the LCR at 1 and 2 years were 75% (6/8) and 60% (3/5), respectively; the median PFS and OS were 8 and 12 months, respectively; and the OS rate at 6, 12, and 24 months after implantation was 91.67%, 66.67%, and 41.67%, respectively. No surgery-related deaths occurred. During the follow-up period, mild complications were observed in patients, including worsening cough, hemoptysis, and pneumothorax.

Conclusions: CT-guided 125I seed implantation therapy is a safe and effective supplementary treatment for SCLC patients, who cannot tolerate radiotherapy.

目的:探讨CT引导下碘125 (125I)放射性粒子植入治疗小细胞肺癌(SCLC)的疗效。材料和方法:回顾性纳入12例SCLC患者。所有患者均接受ct引导下的125I粒子植入治疗,并随访至死亡、最后一次就诊时间或研究结束时间。主要终点为总缓解率(ORR)。次要终点是局部控制率(LCR)、无进展生存期(PFS)、总生存期(OS)和安全性。结果:所有患者均成功植入125I放射性粒子。植入后2、6、12、24个月的ORR分别为83.3%、63.6%、50%、40%;1年和2年的LCR分别为75%(6/8)和60% (3/5);中位PFS和OS分别为8个月和12个月;植入后6、12、24个月的总生存率分别为91.67%、66.67%、41.67%。无手术相关死亡发生。随访期间,患者出现轻微并发症,包括咳嗽加重、咯血、气胸。结论:ct引导下的125I粒子植入治疗对于不能耐受放疗的SCLC患者是一种安全有效的辅助治疗。
{"title":"Computed tomography-guided iodine-125 radioactive seed implantation in small-cell lung cancer: A retrospective study.","authors":"Mengjie Li,&nbsp;Peng Liu,&nbsp;Huan Wang,&nbsp;Biao Wang,&nbsp;Jie Zhou,&nbsp;Yuzhen Jin,&nbsp;Cuicui Wang,&nbsp;Jian Yang,&nbsp;Ping Zhang","doi":"10.5114/jcb.2022.123973","DOIUrl":"https://doi.org/10.5114/jcb.2022.123973","url":null,"abstract":"<p><strong>Purpose: </strong>To explore the efficacy of computed tomography (CT)-guided iodine-125 (<sup>125</sup>I) radioactive seed implantation for the treatment of small-cell lung cancer (SCLC).</p><p><strong>Material and methods: </strong>A total of 12 SCLC patients were retrospectively enrolled. All patients underwent CT-guided <sup>125</sup>I seed implantation therapy, and were followed up until death, the last visit time, or study end time. Primary endpoint was the overall response rate (ORR). Secondary endpoints were local control rate (LCR), progression-free survival (PFS), overall survival (OS), and safety.</p><p><strong>Results: </strong>All patients were successfully implanted with <sup>125</sup>I radioactive seeds. The ORR at 2, 6, 12, and 24 months after implantation was 83.3%, 63.6%, 50%, and 40%, respectively; the LCR at 1 and 2 years were 75% (6/8) and 60% (3/5), respectively; the median PFS and OS were 8 and 12 months, respectively; and the OS rate at 6, 12, and 24 months after implantation was 91.67%, 66.67%, and 41.67%, respectively. No surgery-related deaths occurred. During the follow-up period, mild complications were observed in patients, including worsening cough, hemoptysis, and pneumothorax.</p><p><strong>Conclusions: </strong>CT-guided <sup>125</sup>I seed implantation therapy is a safe and effective supplementary treatment for SCLC patients, who cannot tolerate radiotherapy.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/3e/JCB-14-49843.PMC9924147.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9330981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A retrospective study on unresectable or inoperable head and neck cancers treated with stereotactic ablative brachytherapy. 立体定向近距离消融治疗不可切除或不能手术的头颈部肿瘤的回顾性研究。
IF 1.4 4区 医学 Q3 Medicine Pub Date : 2022-12-01 DOI: 10.5114/jcb.2022.123971
Genghao Zhao, Zhe Wang, Chuang Li, Songbai Chen, Liang Yang, Jinyu Wu, Dong Zhou, Zaishaung Ju, Jun Zhou, Ruoyu Wang

Purpose: The aim of the present study was to assess the clinical efficacy and safety of stereotactic ablative brachytherapy (SABT) for unresectable or inoperable head and neck cancers.

Material and methods: This study retrospectively assessed clinical data of 37 patients with unresectable or inoperable head and neck cancers treated with SABT from October 2016 to October 2021. Variables evaluated included local efficacy, local control rate (LCR), overall survival (OS) rate, and radiological adverse effects.

Results: The median follow-up was of 34 months (range, 5-59 months), and LCR at 6, 12, and 24 months was 89.2%, 78.2%, and 69.4%, respectively. The median survival time was 16 months [95% confidence interval (CI): 10.5-21.5 months], and the OS rate at 6, 12, and 24 months was 97.3%, 70.3%, and 34.5%, respectively. The results of univariate analysis revealed that the type of pathology and gross tumor volume (GTV) D90 were related to LCR (p < 0.05). However, the type of pathology, GTV D90, age, and implantation site were related to OS rate (p < 0.05). The results of multivariate analysis showed that the type of pathology and GTV D90 were substantially related to LCR and OS rate (p < 0.05). The evaluation of post-operative radiological adverse reactions revealed that seven cases (18.9%) developed grade 1-2 skin reactions, four cases (10.8%) developed grade 1-2 oral mucosal outcomes, and no cases developed grade 3 or higher adverse reactions. Post-operative seed dislocation occurred in three patients with tongue cancer.

Conclusions: SABT has produced good local control and mild adverse reactions in the treatment of unresectable or inoperable head and neck cancers. Additionally, it is safe, feasible, minimally invasive, and has fewer adverse effects than other treatment modalities.

目的:本研究的目的是评估立体定向近距离消融治疗(SABT)治疗不可切除或不能手术的头颈癌的临床疗效和安全性。材料和方法:本研究回顾性评估2016年10月至2021年10月37例接受SABT治疗的不能切除或不能手术的头颈癌患者的临床资料。评估的变量包括局部疗效、局部控制率(LCR)、总生存率(OS)和放射不良反应。结果:中位随访时间为34个月(5-59个月),6、12、24个月的LCR分别为89.2%、78.2%、69.4%。中位生存时间为16个月[95%可信区间(CI): 10.5-21.5个月],6个月、12个月和24个月的OS率分别为97.3%、70.3%和34.5%。单因素分析结果显示,病理类型和肿瘤总体积(GTV) D90与LCR相关(p < 0.05)。病理类型、GTV D90、年龄、植入部位与OS率相关(p < 0.05)。多因素分析结果显示,病理类型和GTV D90与LCR和OS率显著相关(p < 0.05)。术后放射学不良反应评价显示,7例(18.9%)出现1-2级皮肤反应,4例(10.8%)出现1-2级口腔黏膜反应,无3级及以上不良反应。舌癌患者术后发生舌核脱位3例。结论:SABT治疗不能切除或不能手术的头颈部肿瘤具有良好的局部控制性和轻微的不良反应。此外,与其他治疗方式相比,它安全、可行、微创且副作用少。
{"title":"A retrospective study on unresectable or inoperable head and neck cancers treated with stereotactic ablative brachytherapy.","authors":"Genghao Zhao,&nbsp;Zhe Wang,&nbsp;Chuang Li,&nbsp;Songbai Chen,&nbsp;Liang Yang,&nbsp;Jinyu Wu,&nbsp;Dong Zhou,&nbsp;Zaishaung Ju,&nbsp;Jun Zhou,&nbsp;Ruoyu Wang","doi":"10.5114/jcb.2022.123971","DOIUrl":"https://doi.org/10.5114/jcb.2022.123971","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of the present study was to assess the clinical efficacy and safety of stereotactic ablative brachytherapy (SABT) for unresectable or inoperable head and neck cancers.</p><p><strong>Material and methods: </strong>This study retrospectively assessed clinical data of 37 patients with unresectable or inoperable head and neck cancers treated with SABT from October 2016 to October 2021. Variables evaluated included local efficacy, local control rate (LCR), overall survival (OS) rate, and radiological adverse effects.</p><p><strong>Results: </strong>The median follow-up was of 34 months (range, 5-59 months), and LCR at 6, 12, and 24 months was 89.2%, 78.2%, and 69.4%, respectively. The median survival time was 16 months [95% confidence interval (CI): 10.5-21.5 months], and the OS rate at 6, 12, and 24 months was 97.3%, 70.3%, and 34.5%, respectively. The results of univariate analysis revealed that the type of pathology and gross tumor volume (GTV) D<sub>90</sub> were related to LCR (<i>p</i> < 0.05). However, the type of pathology, GTV D<sub>90</sub>, age, and implantation site were related to OS rate (<i>p</i> < 0.05). The results of multivariate analysis showed that the type of pathology and GTV D<sub>90</sub> were substantially related to LCR and OS rate (<i>p</i> < 0.05). The evaluation of post-operative radiological adverse reactions revealed that seven cases (18.9%) developed grade 1-2 skin reactions, four cases (10.8%) developed grade 1-2 oral mucosal outcomes, and no cases developed grade 3 or higher adverse reactions. Post-operative seed dislocation occurred in three patients with tongue cancer.</p><p><strong>Conclusions: </strong>SABT has produced good local control and mild adverse reactions in the treatment of unresectable or inoperable head and neck cancers. Additionally, it is safe, feasible, minimally invasive, and has fewer adverse effects than other treatment modalities.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/1e/JCB-14-49841.PMC9924145.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9330986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reliability of algebraic sum to evaluate adjuvant pelvic radiotherapy and vaginal cuff brachytherapy cumulative doses in uterine cancers. 评估子宫癌辅助盆腔放疗和阴道袖带近距离放疗累积剂量的代数和可靠性。
IF 1.4 4区 医学 Q3 Medicine Pub Date : 2022-10-01 DOI: 10.5114/jcb.2022.121175
Michelina Casale, Lorena Draghini, Fabio Trippa, Sara Costantini, Lisa Vicenzi, Letizia Tesei, Alessandro Di Marzo, Fabio Arcidiacono, Marco Italiani, Ernesto Maranzano

Purpose: To evaluate the reliability of algebraic sum with respect to rigid fusion of treatment plans related to adjuvant external beam pelvic radiotherapy (APR) and vaginal cuff high-dose-rate brachytherapy (BT) in uterine cancer patients.

Material and methods: For algebraic sum, APR and BT doses were mathematically added. Rigid fusion was realized overlapping computed tomography (CT) images of APR and BT treatment plans. Rectum and bladder were considered reference organs at risk (OARs). Following dose (D) parameters were examined: Dmax (0.5 cc), D20% and D50% for rectum, Dmax (0.5 cc) and D50% for bladder; for each parameter, differences between the two adopted methods were reported as Δ-values.

Results: Twenty uterine cancer patients submitted to radical surgery followed by APR plus vaginal cuff BT were reviewed. APR was done with a dose of 25 × 2 Gy. All patients also receveid a vaginal cuff boost with BT at the dose of 2 × 5 Gy. Differences between mean cumulative doses calculated with rigid fusion and algebraic sum were evaluated. For the rectum and bladder ΔD50%, there were no significant differences, and BT contribution resulted minimal. An apparent significant difference value was registered in bladder ΔDmax (0.5 cc). No toxicity was observed.

Conclusions: In uterine cancer patients submitted to APR and vaginal cuff BT, algebraic sum and rigid plan fusion of doses allowed to obtain similar results in evaluating cumulative OARs' doses. Further investigations and increased number of patients are recommended to confirm our findings.

目的:评价子宫癌患者辅助外束盆腔放疗(APR)与阴道袖带高剂量率近距离放疗(BT)治疗方案刚性融合的代数和可靠性。材料与方法:用数学方法将APR和BT剂量相加进行代数求和。将APR和BT治疗方案的CT图像重叠进行刚性融合。直肠和膀胱被认为是危险参考器官(OARs)。检测以下剂量(D)参数:直肠Dmax (0.5 cc)、D20%和D50%,膀胱Dmax (0.5 cc)和D50%;对于每个参数,两种方法之间的差异报告为Δ-values。结果:回顾性分析20例子宫癌根治术后行APR +阴道袖带BT治疗的病例。APR的剂量为25 × 2 Gy。所有患者还接受了2 × 5 Gy剂量的BT阴道袖带增强。用刚性融合和代数和计算的平均累积剂量之间的差异进行了评估。对于直肠和膀胱ΔD50%,没有显著差异,BT的贡献最小。膀胱ΔDmax (0.5 cc)有显著差异。未观察到毒性。结论:子宫癌患者行APR和阴道袖带BT时,剂量的代数和和和刚性计划融合可获得相似的剂量评价结果。建议进一步调查和增加患者数量来证实我们的发现。
{"title":"Reliability of algebraic sum to evaluate adjuvant pelvic radiotherapy and vaginal cuff brachytherapy cumulative doses in uterine cancers.","authors":"Michelina Casale,&nbsp;Lorena Draghini,&nbsp;Fabio Trippa,&nbsp;Sara Costantini,&nbsp;Lisa Vicenzi,&nbsp;Letizia Tesei,&nbsp;Alessandro Di Marzo,&nbsp;Fabio Arcidiacono,&nbsp;Marco Italiani,&nbsp;Ernesto Maranzano","doi":"10.5114/jcb.2022.121175","DOIUrl":"https://doi.org/10.5114/jcb.2022.121175","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the reliability of algebraic sum with respect to rigid fusion of treatment plans related to adjuvant external beam pelvic radiotherapy (APR) and vaginal cuff high-dose-rate brachytherapy (BT) in uterine cancer patients.</p><p><strong>Material and methods: </strong>For algebraic sum, APR and BT doses were mathematically added. Rigid fusion was realized overlapping computed tomography (CT) images of APR and BT treatment plans. Rectum and bladder were considered reference organs at risk (OARs). Following dose (D) parameters were examined: D<sub>max</sub> (0.5 cc), D<sub>20%</sub> and D<sub>50%</sub> for rectum, D<sub>max</sub> (0.5 cc) and D<sub>50%</sub> for bladder; for each parameter, differences between the two adopted methods were reported as Δ-values.</p><p><strong>Results: </strong>Twenty uterine cancer patients submitted to radical surgery followed by APR plus vaginal cuff BT were reviewed. APR was done with a dose of 25 × 2 Gy. All patients also receveid a vaginal cuff boost with BT at the dose of 2 × 5 Gy. Differences between mean cumulative doses calculated with rigid fusion and algebraic sum were evaluated. For the rectum and bladder ΔD<sub>50%</sub>, there were no significant differences, and BT contribution resulted minimal. An apparent significant difference value was registered in bladder ΔD<sub>max</sub> (0.5 cc). No toxicity was observed.</p><p><strong>Conclusions: </strong>In uterine cancer patients submitted to APR and vaginal cuff BT, algebraic sum and rigid plan fusion of doses allowed to obtain similar results in evaluating cumulative OARs' doses. Further investigations and increased number of patients are recommended to confirm our findings.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8e/fa/JCB-14-48174.PMC9720693.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10722004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-fraction high-dose-rate brachytherapy: a scoping review on outcomes and toxicities for all disease sites. 单次高剂量率近距离放射治疗:对所有疾病部位的结果和毒性的范围综述
IF 1.4 4区 医学 Q3 Medicine Pub Date : 2022-10-01 DOI: 10.5114/jcb.2022.121477
Mehdi Kazemi, Sarah Nadarajan, Mitchell Kamrava

Purpose: Brachytherapy is well positioned to safely deliver highly conformal single-fraction doses of radiation, which can lower costs and improve efficiency. Traditionally, high-dose-rate brachytherapy (HDR-BT) has been delivered over multiple treatments. A scoping literature review was conducted to better understand the available literature on single-fraction HDR-BT for all disease sites.

Material and methods: According to preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, PubMed database was queried from 1994-2021 using the following search terms: 'brachytherapy', 'high-dose-rate', and 'single-fraction'. A total of 53 studies met our exclusion criteria.

Results: Liver had the highest number of studies, with a total of 618 patients treated with doses ranging from 8 to 25 Gy. Median follow-up ranged from 11-33 months. Local control (LC) rates ranged from 37% to 98%. G3 acute/late toxicities or higher were reported in 3 patients. Prostate cancer included a total of 1,474 patients treated with doses ranging from 19 to 21 Gy. Median follow-up ranged from 20 to 72 months. Prostate specific antigen (PSA) control outcomes after definitive treatment ranged from 65% to 94%, and salvage treatments from 5% to 84%. G3 acute/late toxicities or higher ranged from 0 to 6%. Breast cancer included a total of 268 patients treated with doses ranging from 16 to 20 Gy. Median follow-up ranged from 24 to 72 months. LC rates were 100%. G3 acute toxicities or higher ranged from 0 to 6%. Regarding other cancers, conclusions were limited given the small number of patients within each respective site.

Conclusions: Currently used regimens appear safe, but efficacy vary by different disease sites. Outcomes are more promising for breast and liver, while are less encouraging for prostate. Additional prospective evaluation of single-fraction HDR-BT regimens are warranted.

目的:近距离放射治疗是一种安全、高适形的单组分放射治疗,可以降低成本,提高效率。传统上,高剂量率近距离放射治疗(HDR-BT)是在多次治疗中进行的。为了更好地了解所有疾病部位单组分HDR-BT的现有文献,进行了范围文献综述。材料和方法:根据系统评价和荟萃分析(PRISMA)指南的首选报告项目,使用以下搜索词查询PubMed数据库1994-2021年的数据:“近距离治疗”、“高剂量率”和“单组分”。共有53项研究符合我们的排除标准。结果:肝脏的研究数量最多,共618例患者,剂量范围为8 - 25 Gy。中位随访时间为11-33个月。局部控制率从37%到98%不等。3例患者报告G3急性/晚期或以上毒性。前列腺癌共包括1,474名接受19至21戈瑞剂量治疗的患者。中位随访时间为20至72个月。明确治疗后的前列腺特异性抗原(PSA)控制结果从65%到94%不等,挽救治疗后的结果从5%到84%不等。G3急性/晚期或更高的毒性范围为0 - 6%。乳腺癌共包括268名接受16至20戈瑞剂量治疗的患者。中位随访时间为24至72个月。信用证利率为100%。G3急性毒性或更高的毒性范围为0 - 6%。至于其他癌症,由于每个部位的患者数量较少,因此结论有限。结论:目前使用的方案似乎是安全的,但疗效因不同的疾病部位而异。乳房和肝脏的治疗结果更有希望,而前列腺则不那么令人鼓舞。需要对单组分HDR-BT方案进行额外的前瞻性评估。
{"title":"Single-fraction high-dose-rate brachytherapy: a scoping review on outcomes and toxicities for all disease sites.","authors":"Mehdi Kazemi,&nbsp;Sarah Nadarajan,&nbsp;Mitchell Kamrava","doi":"10.5114/jcb.2022.121477","DOIUrl":"https://doi.org/10.5114/jcb.2022.121477","url":null,"abstract":"<p><strong>Purpose: </strong>Brachytherapy is well positioned to safely deliver highly conformal single-fraction doses of radiation, which can lower costs and improve efficiency. Traditionally, high-dose-rate brachytherapy (HDR-BT) has been delivered over multiple treatments. A scoping literature review was conducted to better understand the available literature on single-fraction HDR-BT for all disease sites.</p><p><strong>Material and methods: </strong>According to preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, PubMed database was queried from 1994-2021 using the following search terms: 'brachytherapy', 'high-dose-rate', and 'single-fraction'. A total of 53 studies met our exclusion criteria.</p><p><strong>Results: </strong>Liver had the highest number of studies, with a total of 618 patients treated with doses ranging from 8 to 25 Gy. Median follow-up ranged from 11-33 months. Local control (LC) rates ranged from 37% to 98%. G3 acute/late toxicities or higher were reported in 3 patients. Prostate cancer included a total of 1,474 patients treated with doses ranging from 19 to 21 Gy. Median follow-up ranged from 20 to 72 months. Prostate specific antigen (PSA) control outcomes after definitive treatment ranged from 65% to 94%, and salvage treatments from 5% to 84%. G3 acute/late toxicities or higher ranged from 0 to 6%. Breast cancer included a total of 268 patients treated with doses ranging from 16 to 20 Gy. Median follow-up ranged from 24 to 72 months. LC rates were 100%. G3 acute toxicities or higher ranged from 0 to 6%. Regarding other cancers, conclusions were limited given the small number of patients within each respective site.</p><p><strong>Conclusions: </strong>Currently used regimens appear safe, but efficacy vary by different disease sites. Outcomes are more promising for breast and liver, while are less encouraging for prostate. Additional prospective evaluation of single-fraction HDR-BT regimens are warranted.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/01/94/JCB-14-48268.PMC9720691.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10722000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Superficial high-dose-rate brachytherapy for primary tumors and relapses after surgery in patients with basal cell carcinoma of the head and neck region: results of a retrospective comparative cohort study. 浅表高剂量率近距离放射治疗头颈部基底细胞癌原发肿瘤和术后复发:一项回顾性比较队列研究的结果
IF 1.4 4区 医学 Q3 Medicine Pub Date : 2022-10-01 DOI: 10.5114/jcb.2022.121134
Artur J Chyrek, Adam Chicheł, Wojciech M Burchardt, Grzegorz Bielęda, Małgorzata Jankowska, Jerzy Moczko, Andrzej Roszak

Purpose: The recommended treatments for basal cell carcinoma (BCC) in the head and neck (H&N) region are Mohs surgery, standard surgical excision (SSE), and radiotherapy. According to the literature, local recurrence after surgical treatment in this area is associated with a worse prognosis in case of re-treatment. To our knowledge, there are no reports on high-dose-rate brachytherapy (HDR-BT) for BCC of the H&N region, both in primary lesions and relapses after SSE. This study aimed to fill this gap in the literature.

Material and methods: Inclusion criteria were pathologically confirmed BCC, tumor location in the H&N region, treatment performed with superficial HDR-BT, and a minimum follow-up of 12 months. An analysis was performed on a group of 90 patients, in whom a total of 102 tumors were treated. Subsequently, tumors were divided into two sub-groups, including those treated initially, and treated due to local recurrence after previous SSE. Primary treatment group (PrG) included 59 tumors, whereas 43 tumors were included in recurrent group (ReG).

Results: Statistical analysis did not reveal any significant differences between the groups in terms of age (p = 0.43), treatment duration (p = 0.17), follow-up time (p = 0.96), sex (p = 0.18), local advancement (p = 0.83), and location (p = 0.68). The estimated 5-year relapse-free survival was 96.4% in the PrG and 94.6% in the ReG group, and the difference was not statistically significant (p = 0.72). In the PrG, skin toxicity was as follows: early G1 - 20.3%, G2 - 28.8%, G3 - 42.4%, G4 - 8.5%; late G1 - 33.9%, G2 - 50.8%, G3 - 1.7%, G4 - 11.9%. Whereas, in the ReG, toxicity was as follows: early G1 - 16.3%, G2 - 41.9%, G3 - 37.2%, G4 - 4.6%; late G1 - 30.2%, G2 - 62.8%, G3 - 4.6%. There were no statistically significant differences in the early nor late toxicity between the groups (p = 0.54, p = 0.16).

Conclusions: Superficial HDR-BT is a highly effective treatment for both primary and recurrent BCC of the H&N region, and is associated with acceptable skin toxicity.

目的:头颈部基底细胞癌(BCC)推荐的治疗方法是Mohs手术、标准手术切除(SSE)和放疗。据文献报道,该部位手术治疗后局部复发,再治疗预后较差。据我们所知,没有关于H&N地区BCC的高剂量率近距离放疗(HDR-BT)的报道,无论是原发性病变还是SSE后复发。本研究旨在填补这一文献空白。材料和方法:纳入标准为病理证实的BCC,肿瘤位于H&N区,行浅表HDR-BT治疗,至少随访12个月。对90名患者进行了分析,其中总共治疗了102个肿瘤。随后,将肿瘤分为两组,包括首次治疗组和既往SSE后局部复发治疗组。原发性治疗组(PrG)纳入59例肿瘤,复发组(ReG)纳入43例肿瘤。结果:组间年龄(p = 0.43)、治疗时间(p = 0.17)、随访时间(p = 0.96)、性别(p = 0.18)、局部进展(p = 0.83)、部位(p = 0.68)差异无统计学意义。PrG组估计5年无复发生存率为96.4%,ReG组为94.6%,差异无统计学意义(p = 0.72)。在PrG中,早期G1 - 20.3%, G2 - 28.8%, G3 - 42.4%, G4 - 8.5%;晚G1 - 33.9%, G2 - 50.8%, G3 - 1.7%, G4 - 11.9%。而在ReG中,早期G1 - 16.3%, G2 - 41.9%, G3 - 37.2%, G4 - 4.6%;G1 - 30.2%, G2 - 62.8%, G3 - 4.6%。两组早期、晚期毒性比较,差异均无统计学意义(p = 0.54, p = 0.16)。结论:浅表HDR-BT是治疗H&N地区原发性和复发性BCC的一种非常有效的方法,并且与可接受的皮肤毒性相关。
{"title":"Superficial high-dose-rate brachytherapy for primary tumors and relapses after surgery in patients with basal cell carcinoma of the head and neck region: results of a retrospective comparative cohort study.","authors":"Artur J Chyrek,&nbsp;Adam Chicheł,&nbsp;Wojciech M Burchardt,&nbsp;Grzegorz Bielęda,&nbsp;Małgorzata Jankowska,&nbsp;Jerzy Moczko,&nbsp;Andrzej Roszak","doi":"10.5114/jcb.2022.121134","DOIUrl":"https://doi.org/10.5114/jcb.2022.121134","url":null,"abstract":"<p><strong>Purpose: </strong>The recommended treatments for basal cell carcinoma (BCC) in the head and neck (H&N) region are Mohs surgery, standard surgical excision (SSE), and radiotherapy. According to the literature, local recurrence after surgical treatment in this area is associated with a worse prognosis in case of re-treatment. To our knowledge, there are no reports on high-dose-rate brachytherapy (HDR-BT) for BCC of the H&N region, both in primary lesions and relapses after SSE. This study aimed to fill this gap in the literature.</p><p><strong>Material and methods: </strong>Inclusion criteria were pathologically confirmed BCC, tumor location in the H&N region, treatment performed with superficial HDR-BT, and a minimum follow-up of 12 months. An analysis was performed on a group of 90 patients, in whom a total of 102 tumors were treated. Subsequently, tumors were divided into two sub-groups, including those treated initially, and treated due to local recurrence after previous SSE. Primary treatment group (PrG) included 59 tumors, whereas 43 tumors were included in recurrent group (ReG).</p><p><strong>Results: </strong>Statistical analysis did not reveal any significant differences between the groups in terms of age (<i>p</i> = 0.43), treatment duration (<i>p</i> = 0.17), follow-up time (<i>p</i> = 0.96), sex (<i>p</i> = 0.18), local advancement (<i>p</i> = 0.83), and location (<i>p</i> = 0.68). The estimated 5-year relapse-free survival was 96.4% in the PrG and 94.6% in the ReG group, and the difference was not statistically significant (<i>p</i> = 0.72). In the PrG, skin toxicity was as follows: early G1 - 20.3%, G2 - 28.8%, G3 - 42.4%, G4 - 8.5%; late G1 - 33.9%, G2 - 50.8%, G3 - 1.7%, G4 - 11.9%. Whereas, in the ReG, toxicity was as follows: early G1 - 16.3%, G2 - 41.9%, G3 - 37.2%, G4 - 4.6%; late G1 - 30.2%, G2 - 62.8%, G3 - 4.6%. There were no statistically significant differences in the early nor late toxicity between the groups (<i>p</i> = 0.54, <i>p</i> = 0.16).</p><p><strong>Conclusions: </strong>Superficial HDR-BT is a highly effective treatment for both primary and recurrent BCC of the H&N region, and is associated with acceptable skin toxicity.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/3e/JCB-14-48160.PMC9720694.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10722002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comparative study of dosimetric parameters of 3D-printed non-coplanar template-assisted CT-guided iodine-125 seed implantation brachytherapy in patients with inguinal lymph node metastatic carcinomas. 3d打印非共面模板辅助ct引导下碘125粒子近距离植入治疗腹股沟淋巴结转移癌剂量学参数的比较研究
IF 1.4 4区 医学 Q3 Medicine Pub Date : 2022-10-01 DOI: 10.5114/jcb.2022.121564
Yanhao Liu, Zongyan Shen, Ang Qu, Ping Jiang, Yuliang Jiang, Junjie Wang

Purpose: To compare the pre-plan and post-plan dosimetric parameter differences of 3D-printed non-coplanar templates (3D-PNCT)-assisted computed tomography (CT)-guided iodine-125 (125I) radioactive seed implantation brachytherapy (RISI) in patients with inguinal lymph node metastasis (ILNM).

Material and methods: This was a retrospective study of 15 patients with ILNM carcinomas treated with 3D-PNCT-assisted CT-guided RISI between May, 2015 and April, 2018. All patients underwent prior external beam radiotherapy (EBRT) or surgery. Dosimetric parameters included D90, D100 (dose delivered to 90% and 100% of the volume, respectively), V100, V150, V200 (percentage of target volume receiving 100%, 150%, and 200% of the prescribed dose, respectively). Quality parameters included conformal index (CI), external index (EI), and homogeneity index (HI). Paired t-test and Bland-Altman analysis were applied to compared pre-plan and post-plan parameters.

Results: The median gross tumor volume (GTV) in the pre-plan was 8.7 ml (range, 0.8-185.1 ml). There were statistically significant differences in V100, V150, CI, and EI (p < 0.05). Bland-Altman analysis indicated that accidental error of RISI was small. In 1 of the 15 cases, D90 and D100 exceeded the prescribed therapeutic accuracy. In 1 of the 15 cases, V150, EI, and GTV were outside the specified accuracy range (95% confidence interval).

Conclusions: 3D-PNCT-assisted CT-guided RISI is a safe, accurate, and feasible choice in ILNM treatment. The procedure of RISI has significantly improved. The pre-plan can be accurately executed by 3D-PNCT-assisted CT-guided RISI.

目的:比较3d打印非共面模板(3D-PNCT)辅助计算机断层扫描(CT)引导碘-125 (125I)放射性粒子植入近距离放射治疗(RISI)治疗腹股沟淋巴结转移(ILNM)患者的术前和术后剂量学参数差异。材料和方法:本研究是一项回顾性研究,2015年5月至2018年4月,15例il - nm癌患者接受3d - pnct辅助ct引导的RISI治疗。所有患者均接受过体外放射治疗(EBRT)或手术。剂量学参数包括D90、D100(分别达到体积的90%和100%的剂量)、V100、V150、V200(分别达到规定剂量的100%、150%和200%的靶体积百分比)。质量参数包括保形指数(CI)、外部指数(EI)和均匀性指数(HI)。采用配对t检验和Bland-Altman分析比较计划前后参数。结果:术前总肿瘤体积(GTV)中位数为8.7 ml(范围0.8 ~ 185.1 ml)。V100、V150、CI、EI差异有统计学意义(p < 0.05)。Bland-Altman分析表明,RISI的意外误差较小。15例中有1例D90和D100超过了规定的治疗准确性。15例中有1例的V150、EI和GTV在规定的准确度范围(95%置信区间)之外。结论:3d - pnct辅助ct引导下的RISI治疗ILNM是一种安全、准确、可行的选择。RISI的程序有了明显的改进。3d - pnct辅助ct引导下的RISI可以准确执行预先计划。
{"title":"A comparative study of dosimetric parameters of 3D-printed non-coplanar template-assisted CT-guided iodine-125 seed implantation brachytherapy in patients with inguinal lymph node metastatic carcinomas.","authors":"Yanhao Liu,&nbsp;Zongyan Shen,&nbsp;Ang Qu,&nbsp;Ping Jiang,&nbsp;Yuliang Jiang,&nbsp;Junjie Wang","doi":"10.5114/jcb.2022.121564","DOIUrl":"https://doi.org/10.5114/jcb.2022.121564","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the pre-plan and post-plan dosimetric parameter differences of 3D-printed non-coplanar templates (3D-PNCT)-assisted computed tomography (CT)-guided iodine-125 (<sup>125</sup>I) radioactive seed implantation brachytherapy (RISI) in patients with inguinal lymph node metastasis (ILNM).</p><p><strong>Material and methods: </strong>This was a retrospective study of 15 patients with ILNM carcinomas treated with 3D-PNCT-assisted CT-guided RISI between May, 2015 and April, 2018. All patients underwent prior external beam radiotherapy (EBRT) or surgery. Dosimetric parameters included D<sub>90</sub>, D<sub>100</sub> (dose delivered to 90% and 100% of the volume, respectively), V<sub>100</sub>, V<sub>150</sub>, V<sub>200</sub> (percentage of target volume receiving 100%, 150%, and 200% of the prescribed dose, respectively). Quality parameters included conformal index (CI), external index (EI), and homogeneity index (HI). Paired <i>t</i>-test and Bland-Altman analysis were applied to compared pre-plan and post-plan parameters.</p><p><strong>Results: </strong>The median gross tumor volume (GTV) in the pre-plan was 8.7 ml (range, 0.8-185.1 ml). There were statistically significant differences in V<sub>100</sub>, V<sub>150</sub>, CI, and EI (<i>p</i> < 0.05). Bland-Altman analysis indicated that accidental error of RISI was small. In 1 of the 15 cases, D<sub>90</sub> and D<sub>100</sub> exceeded the prescribed therapeutic accuracy. In 1 of the 15 cases, V<sub>150</sub>, EI, and GTV were outside the specified accuracy range (95% confidence interval).</p><p><strong>Conclusions: </strong>3D-PNCT-assisted CT-guided RISI is a safe, accurate, and feasible choice in ILNM treatment. The procedure of RISI has significantly improved. The pre-plan can be accurately executed by 3D-PNCT-assisted CT-guided RISI.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9e/66/JCB-14-48290.PMC9720692.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10722006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Overcoming pubic arch interference in prostate brachytherapy using steerable needles. 在前列腺近距离定向针治疗中克服耻骨弓干扰。
IF 1.4 4区 医学 Q3 Medicine Pub Date : 2022-10-01 DOI: 10.5114/jcb.2022.121562
Martijn de Vries, Sarah L Wilby, Antony L Palmer, Wojciech Polak, Inna O'Hea, Dominic Hodgson, John J van den Dobbelsteen

Purpose: A proportion of patients are not directly eligible for prostate brachytherapy (BT) due to pubic arch interference (PAI). Constraints in positioning sources behind the pubic arch due to linear, horizontal needle paths, may hamper effective irradiation of the target volume. This work evaluated the effect of prostate volume (Vp) and patient posture change on the amount of PAI, and demonstrated that steerable needles may broaden the inclusion criteria for patients with enlarged prostates and observed PAI.

Material and methods: Twenty-seven patients (Vp > 60 cc) were included in this study. Access obstruction to the prostate was evaluated using diagnostic magnetic resonance imaging (MRI) scans, after six upward rotations of the pelvis and the prostate in 5 degree steps, to indicate the effect of patient posture change from supine to lithotomy position. For patients with PAI, we evaluated if the steerable needle could access the obstructed volume of the prostate.

Results: The data showed no clear relation between Vp and PAI. In 23 of the 27 patients, in which PAI was observed, 14 showed obstruction of the prostate of ≥ 10 mm in the supine position (mean PAI ± standard deviation: 15.2 ±3.8 mm). Anatomical rotation reduced PAI by 4.8 mm after every 10 degrees of upward rotation, still resulting in obstructions of 8.1 ±2.4 mm in 10 of the 14 cases after 15 degree rotation. The steerable needle enabled access to all the required coordinates of the prostate.

Conclusions: The ability to steer along curved paths enables prostate BT in patients with enlarged prostates and PAI, and reduces the change of needing to abandon treatment.

目的:一部分患者由于耻骨弓干扰(PAI)不能直接接受前列腺近距离放射治疗(BT)。由于直线、水平的穿刺针路径,在耻骨弓后方定位光源受限,可能会妨碍对目标体积的有效照射。本研究评估了前列腺体积(Vp)和患者姿势改变对PAI的影响,并证明可操纵针可拓宽前列腺肥大患者和观察PAI的纳入标准。材料和方法:本研究纳入27例Vp > 60 cc的患者。通过诊断性磁共振成像(MRI)扫描,在骨盆和前列腺以5度的步骤向上旋转6次后,评估前列腺通路阻塞,以指示患者从仰卧位到取石位的姿势改变的影响。对于PAI患者,我们评估了可引导针是否能进入阻塞的前列腺体积。结果:血凝素与PAI无明显关系。27例患者中有23例出现PAI,其中14例在仰卧位时前列腺梗阻≥10 mm (PAI平均值±标准差:15.2±3.8 mm)。解剖旋转每向上旋转10度,PAI降低4.8 mm,但旋转15度后,14例中仍有10例出现8.1±2.4 mm的阻塞。可操纵的针头可以进入前列腺的所有需要的坐标。结论:在前列腺肥大和PAI患者中,弯曲路径引导的能力使前列腺BT得以实现,并减少了需要放弃治疗的变化。
{"title":"Overcoming pubic arch interference in prostate brachytherapy using steerable needles.","authors":"Martijn de Vries,&nbsp;Sarah L Wilby,&nbsp;Antony L Palmer,&nbsp;Wojciech Polak,&nbsp;Inna O'Hea,&nbsp;Dominic Hodgson,&nbsp;John J van den Dobbelsteen","doi":"10.5114/jcb.2022.121562","DOIUrl":"https://doi.org/10.5114/jcb.2022.121562","url":null,"abstract":"<p><strong>Purpose: </strong>A proportion of patients are not directly eligible for prostate brachytherapy (BT) due to pubic arch interference (PAI). Constraints in positioning sources behind the pubic arch due to linear, horizontal needle paths, may hamper effective irradiation of the target volume. This work evaluated the effect of prostate volume (V<sub>p</sub>) and patient posture change on the amount of PAI, and demonstrated that steerable needles may broaden the inclusion criteria for patients with enlarged prostates and observed PAI.</p><p><strong>Material and methods: </strong>Twenty-seven patients (V<sub>p</sub> > 60 cc) were included in this study. Access obstruction to the prostate was evaluated using diagnostic magnetic resonance imaging (MRI) scans, after six upward rotations of the pelvis and the prostate in 5 degree steps, to indicate the effect of patient posture change from supine to lithotomy position. For patients with PAI, we evaluated if the steerable needle could access the obstructed volume of the prostate.</p><p><strong>Results: </strong>The data showed no clear relation between V<sub>p</sub> and PAI. In 23 of the 27 patients, in which PAI was observed, 14 showed obstruction of the prostate of ≥ 10 mm in the supine position (mean PAI ± standard deviation: 15.2 ±3.8 mm). Anatomical rotation reduced PAI by 4.8 mm after every 10 degrees of upward rotation, still resulting in obstructions of 8.1 ±2.4 mm in 10 of the 14 cases after 15 degree rotation. The steerable needle enabled access to all the required coordinates of the prostate.</p><p><strong>Conclusions: </strong>The ability to steer along curved paths enables prostate BT in patients with enlarged prostates and PAI, and reduces the change of needing to abandon treatment.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/15/05/JCB-14-48288.PMC9720690.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10722007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Journal of Contemporary Brachytherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1